Healx is a mission-driven technology company pioneering the next generation of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are 7,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AI technology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact.

Traditional drug discovery is slow, expensive and has a 5% success rate. This has led to a culture of filling pipelines with blockbuster drugs, targeted to large patient populations, in order to offset the cost of failures. By using AI and other frontier technologies to redevelop, combine and enhance known compounds, we are building a pipeline of new and effective therapies.

We bring treatments from prediction to patient. Artificial intelligence enables us to rapidly identify which novel drug-disease relationships have the highest chance of success and effectively scale a drug pipeline that will deliver significant patient impact. By using technology to de-risk the drug discovery process, we can run multiple programmes in parallel and deliver a higher chance of treatment success.